ReviewEuropean cardiology2020
Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines.
Review in European cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Expert Review of the Strategies to Optimize Long-Term Outcomes After Coronary Artery Bypass Grafting.Reviews in cardiovascular medicine · 2025Review
- Dual antiplatelet therapy in GI-bleed patients with extensive coronary artery disease history: a systematic review.Annals of medicine and surgery (2012) · 2025Review
- Distribution and Blood Penetration of Hirudin in Various Organs and Tissues of Rabbits With Carotid Artery Injury by Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry.Journal of analytical methods in chemistry · 2025Article
- Platelet-Neutrophil Crosstalk in Thrombosis.International journal of molecular sciences · 2023Review
- Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines.Cureus · 2022Review
- Combined Antiplatelet Therapy Reduces the Proinflammatory Properties of Activated Platelets.TH open : companion journal to thrombosis and haemostasis · 2021Article
- Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap.European cardiology · 2021Review
- Dual Antiplatelet Therapy in Coronary Artery Disease.Cardiology and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual's risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investigated how factors such as antiplatelet selection or duration of treatment can affect outcomes in both stable CAD and acute coronary syndromes. To aid clinicians in the challenge of applying trial findings to the circumstances of individual patients, the American College of Cardiology/American Heart Association and European Society of Cardiology have released focused updates on prescribing DAPT in CAD. While the two guidelines agree on many issues, there are some differences in the recommendations. This article highlights those differences and provides comment on their aetiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.